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Summary
 
Several lines of evidence suggest that host genetic factors controlling the immune response in-
 
fluence infection by 
 
Mycobacterium tuberculosis
 
. The proinflammatory cytokine interleukin (IL)-1
 
b
 
and its antagonist, IL-1Ra (IL-1 receptor agonist), are strongly induced by 
 
M
 
.
 
 tuberculosis
 
 and
are encoded by polymorphic genes. The induction of both IL-1Ra mRNA and secreted pro-
tein by 
 
M
 
.
 
 tuberculosis
 
 in IL-1Ra allele A2–positive (IL-1Ra A2
 
1
 
) healthy subjects was 1.9-fold
 
higher than in IL-1Ra A2
 
2
 
 subjects. The 
 
M
 
.
 
 tuberculosis–
 
induced expression of mRNA for IL-1
 
b
 
was higher in subjects of the IL-1
 
b
 
 (
 
1
 
3953) A1
 
1
 
 haplotype (
 
P
 
 5 
 
0.04). The molar ratio of
IL-1Ra/IL-1
 
b
 
 induced by 
 
M
 
.
 
 tuberculosis
 
 was markedly higher in IL-1Ra A2
 
1
 
 individuals (
 
P
 
 ,
 
0.05), with minor overlap between the groups, reflecting linkage between the IL-1Ra A2 and
IL-1
 
b
 
 (
 
1
 
3953) A2 alleles. In 
 
M
 
.
 
 tuberculosis
 
–stimulated peripheral blood mononuclear cells, the
addition of IL-4 increased IL-1Ra secretion, whereas interferon 
 
g
 
 increased and IL-10 de-
creased IL-1
 
b
 
 production, indicative of a differential influence on the IL-1Ra/IL-1
 
b
 
 ratio by
cytokines. In a study of 114 healthy purified protein derivative–reactive subjects and 89 pa-
tients with tuberculosis, the frequency of allelic variants at two positions (
 
2
 
511 and 
 
1
 
3953) in
the IL-1
 
b
 
 and IL-1Ra genes did not differ between the groups. However, the proinflammatory
IL-1Ra A2
 
2
 
/IL-1
 
b
 
 (
 
1
 
3953) A1
 
1
 
 haplotype was unevenly distributed, being more common in
patients with tuberculous pleurisy (92%) in comparison with healthy 
 
M
 
.
 
 tuberculosis
 
–sensitized
 
control subjects or patients with other disease forms (57%,
 
 P 
 
5 
 
0.028 and 56%,
 
 P 
 
5 
 
0.024, respec-
 
tively). Furthermore, the IL-1Ra A2
 
1
 
 haplotype was associated with a reduced Mantoux response
to purified protein derivative of 
 
M
 
.
 
 tuberculosis
 
: 60% of tuberculin-nonreactive patients were of this
type. Thus, the polymorphism at the IL-1 locus influences the cytokine response and may be a de-
terminant of delayed-type hypersensitivity and disease expression in human tuberculosis.
Key words: interleukin 1 receptor • tuberculosis • susceptibility, disease • hypersensitivity, 
delayed • granuloma
 
B
 
y comparison with other pathogens, widely distributed
isolates of 
 
Mycobacterium tuberculosis
 
 show a striking lack
of antigenic variation (1). The occurrence of tuberculosis
epidemics in populations previously unexposed to 
 
M
 
.
 
 tuber-
culosis 
 
(2, 3) and the twofold risk of disease in identical,
compared with nonidentical, twins (4) indicates a genetic
component in susceptibility. Rare susceptibility to recur-
rent atypical intracellular infection is proved to be con-
 
ferred by mutation in the genes for the IFN-
 
g
 
 receptor (5–
7), the IL-12 receptor (8, 9), or IL-12 (10). However, the
extent to which these severe defects contribute to suscepti-
bility in populations is unknown. In a recent large case-con-
trol study, disease susceptibility in West Africans was con-
ferred by variants of the human 
 
Nramp1
 
 and vitamin D
receptor genes (11, 12). The possibility also exists that disease
expression, as well as susceptibility to tuberculosis per se, is
influenced by the host response. A single genetic isolate of
 
M
 
.
 
 tuberculosis
 
 associated with a disease outbreak caused
highly varied disease manifestations (13), and in earlier popu-
lation-based studies, severe pulmonary tuberculosis has been
associated with both HLA-DR15 and haptoglobin 2-2 (for
review, see reference 14).
A key element in the inflammatory response is the
prompt production of proinflammatory cytokines such as
IL-1
 
b
 
 and TNF-
 
a
 
, required to control infection by 
 
M
 
.
 
 tuber-
 
culosis 
 
(15, 16). To terminate the immune response and
limit the potential for immunopathology, the proinflamma-
tory response is in turn downregulated by cytokines such as
 1864
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TGF-
 
b
 
, IL-10, and, specifically in the case of IL-1
 
b
 
, the IL-1
receptor antagonist (IL-1Ra), a pure antagonist of the IL-1
type 1 receptor (IL-1RI) (17). The genes coding for both
IL-1
 
b
 
 and the IL-1Ra gene are on chromosome 2q. Two bi-
allelic polymorphisms in the IL-1
 
b
 
 gene at positions 
 
2
 
511
and 
 
1
 
3953 relative to the transcriptional start codon have
been described (18, 19). Allele 1 of the 
 
1
 
3953 polymorphism
(IL-1
 
b
 
 
 
1
 
3953 A1
 
1
 
) is associated with moderately increased
IL-1
 
b
 
 production in response to LPS (19). The IL-1Ra gene
is also polymorphic due to a variable number (2–6) of tandem
repeats of 86 bp (VNTR) within its second intron (20). This
polymorphism has been shown to be unambiguously func-
tional at the level of secreted protein, as monocytes from in-
dividuals homo- or heterozygous for allele 2 (IL-1Ra A2
 
1
 
,
 
IL-1RN
 
*
 
2
 
, 2 repeats) produce significantly more IL-1Ra in
response to GM-CSF (21) and also have higher plasma levels
(22). Serum IL-1Ra is known to be elevated in patients with
tuberculosis (23). In addition, the ratio of IL-1Ra to IL-1
 
b
 
 is
elevated in the cerebrospinal fluid of cases of tuberculous, as
compared with pyogenic, meningitis (24). These data suggest
that the expression of IL-1Ra may impact on disease expres-
sion. However, the effect of 
 
M
 
.
 
 tuberculosis
 
 infection on the
secretion of IL-1
 
b
 
 and IL-1Ra in vitro
 
 
 
has not been related
to these polymorphisms nor has the relevance of the latter to
tuberculosis been investigated.
In this study, we found that 
 
M
 
.
 
 tuberculosis–
 
induced IL-1Ra
mRNA and protein secretion in healthy IL-1Ra A2
 
1 
 
sub-
jects was approximately twofold that of IL-1Ra A2
 
2
 
 indi-
viduals. In addition, the molar ratio of IL-1Ra/IL-1
 
b
 
 was
strikingly higher in IL-1Ra A2
 
1
 
 individuals. In 
 
M
 
.
 
 tuber-
culosis
 
–stimulated PBMC, the addition of IL-4 increased
IL-1Ra secretion, whereas IFN-
 
g
 
 increased, and IL-10 de-
creased, IL-1
 
b
 
 production, indicative of a differential influ-
ence on the IL-1Ra/IL-1
 
b
 
 ratio by cytokines. In a pilot
case-control analysis, the IL-1
 
b
 
 and IL-1Ra allele frequen-
cies were not different between patients with tuberculosis
and purified protein derivative (PPD) skin test (Mantoux)–
reactive control subjects. However, the proinflammatory
IL-1Ra A2
 
2
 
/IL-1
 
b
 
 (
 
1
 
3953) A1
 
1
 
 haplotype was unevenly
distributed, being more common in patients with pleural
tuberculosis and less common in extrapulmonary disease.
Furthermore, and consistent with the in vitro observations,
the IL-1Ra A2
 
1
 
 haplotype was associated with a reduced
Mantoux response: 60% of tuberculin-nonreactive patients
were of this type. Thus, the polymorphism at the IL-1 lo-
cus influences the cytokine response to, and may be a de-
terminant of, delayed-type hypersensitivity (DTH)
 
1
 
 and
disease expression in human tuberculosis.
 
Materials and Methods
Study Populations. For cell culture, healthy, PPD skin test–
negative donors from the laboratory staff at Case Western Re-
serve University were bled and genotyped as below. In the pilot
case-control analysis, a different population of 89 unselected pa-
tients and 114 control subjects who were Hindu, residents of
London, and identified as being of Gujarati origin were recruited
from Northwick Park Hospital, Harrow, England. The peak mi-
gration of Gujaratis to west London followed political change in
East Africa in the decade 1970–1980. There is a high incidence of
tuberculosis amongst Gujaratis in Harrow of z128/100,000 (25),
with an unusual excess of extrapulmonary disease in females.
Within this community, 35–65% of marriages are prearranged,
marriage to non-Gujarati Hindus is rare, and marriage to non-
Hindus is exceptional (Patel, P., and R.J. Wilkinson, unpublished
observations). 62% of subjects in this study were bacille Cal-
mette-Guérin vaccinated. All 89 patients (average age 42.3 6 1.7
yr; 56 females and 33 males) had culture- or biopsy-proven tu-
berculosis. All patients had free access to optimal medical care.
The median duration of symptoms at diagnosis was 31 d (21 and
90 d being the 25th and 75th quartile values), thereby minimiz-
ing the effect of chronicity on clinical presentation. The defini-
tion of clinical phenotype was based on the International Classifi-
cation of Disease 9 classification, and the overwhelming majority
of patients were judged to have delayed postprimary (reactiva-
tion) disease. Patients known to be immunosuppressed (e.g., by
HIV infection or corticosteroid therapy) were excluded. Mantoux
testing was performed by the intradermal injection of one tuber-
culin unit of PPD (Evans Medical). The resultant diameter of
transverse induration was recorded after 48 h. This low dose of
tuberculin is routinely used in the United Kingdom to avoid ne-
crotic reactions. All 114 nonconsanguineous (spouses of patients
where possible) healthy controls (average age 42.9 6 1.2 yr; 54
females and 60 males) were recruited from the tuberculosis con-
tact clinic at the same hospital and had documented contact with
tuberculosis (often multiple). All were PPD skin test–positive,
asymptomatic, and had normal chest radiographs. 10/114 (8.7%)
received chemoprophylaxis. These subjects were recruited be-
tween June 1995 and May 1998; in June 1998, all remained dis-
ease free. Ethical permission for this case-control analysis was ob-
tained from the Harrow local research ethical committee (EC1646).
IL-1Ra and IL-1b Genotypes. The genotypes were determined
as previously described (20, 22). DNA was isolated by phenol-
chloroform extraction, and 5 ng was used in the PCR amplifica-
tion of the IL-1Ra VNTR region, using 0.05 mM of the following
primers: 59-TCC TGG TCT GCA GGT AA-39 and 59-CTC
AGC AAC ACT CCT AT-39. The mixture was heated to 968C
for 1 min, followed by 30 cycles of 948C for 1 min, 608C for 1 min,
708C for 1 min, and then a final 7 min at 708C. Products were
run on an ethidium bromide–stained, 1.5% agarose MR gel (Boeh-
ringer Mannheim) and visualized directly. A 304-bp fragment of
the IL-1b gene from 2702 to 2398 was amplified using the fol-
lowing primers: 59-TGG CAT TGA TCT GGT TCA TC-39
and 59-GTT TAG GAA TCT TCC CAC TT-39, using the same
cycling conditions as above. The products were digested over-
night at 378C with 5 U Ava 1 and run on a 2.5% gel as above, gen-
erating the following patterns: single band of 304 bp, A2/A2
homozygote; two bands at 190 and 114 bp, A1/A1 homozygote; all
three bands, heterozygote. A 249-bp fragment of the IL-1b exon 5
was amplified using the following primers: 59-GTT GTC ATC
AGA CTT TGA CC-39 and 59-TTC AGT TCA TAT GGA
CCA GA-39. The mixture was heated for three cycles of 948C
for 2 min, 558C for 2 min, 748C for 1 min, then 32 cycles of 948C
for 1 min, 558C for 1 min, 748C for 1 min, and then a final 10 min
at 708C. The products were digested overnight at 658C with 2.5 U
Taq 1 and run on a 3% gel, generating the following patterns: single
band of 249 bp, A2/A2 homozygote; two bands at 135 and 114 bp,
A1/A1 homozygote; all three bands, heterozygote.
1Abbreviations used in this paper: DTH, delayed-type hypersensitivity; PPD,
purified protein derivative; rt, room temperature.
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Cell Culture. PBMCs were separated over a Ficoll (Pharma-
cia Biotech) gradient. Preliminary experiments established that
conventional separation of monocytes by adherence to plastic,
harvesting, and replating led to spontaneous release of IL-1Ra.
To reduce such activation, freshly isolated PBMCs were cultured
at 2.5 3 106 /ml in 24-well plates in RPMI 1640 (Biowhittaker)
without antibiotics in the presence of 2% autologous serum. In
each experiment, the number of monocytes present in PBMCs
was determined by washing off nonadherent cells (33) in a dupli-
cate well and then detaching the adherent cells using ice cold
PBS and a cell scraper. Monocyte counts were generally z10% of
the total PBMC numbers. Preliminary experiments showed that
IL-1Ra production under these conditions was detectable by 4 h
and reached a plateau by 10–12 h, with no further significant in-
crease during the next 12 h. There was no significant difference
in production between experiments in which the nonadherent
cells had been removed by washing and wells containing unsepa-
rated PBMC, indicating that the adherent cells were responsible
for the IL-1Ra secretion. We therefore collected, and froze at
2708C, PBMC supernates after 10 h of culture. In some cases,
cell lysates were prepared by adding an equal volume of PBS and
then freeze-thawing once. In this way we established that the ra-
tio of IL-1Ra secreted into the supernate to that remaining in cell
lysates was consistently .10:1, irrespective of time point, stimu-
lus, and genotype.
Reagents. M. tuberculosis H37Ra and H37Rv was prepared
and aliquotted as previously described (26). Aliquots were vor-
texed for 15–20 min before use at an infection ratio of 0.1 or 1
M. tuberculosis bacilli/1 PBMC (corresponding to z1:1 and 10:1
per monocyte). PPD of M. tuberculosis was the gift of Lederle
Labs. (American Cyanamid Co.) and used at 0.1–100 mg/ml.
Recombinant TGF-b, IL-4, and IFN-g, and the neutralizing an-
tibodies to IL-1b (mouse IgG1), IL-6 (polyclonal goat IgG),
TGF-b (polyclonal chicken IgY), and TNF-a (mouse IgG1), and
appropriate isotype control antibodies were purchased from R & D
Systems, Inc. All recombinant cytokines, PPD, M. tuberculosis,
and neutralizing antibodies used were tested for endotoxin con-
tamination by the Limulus amebocyte assay (Biowhittaker) and
were either free or contained very small levels (always ,2ng/mg)
of endotoxin.
Cytokine ELISA. Maxisorp (Nunc, Inc.) plates were coated
overnight at 48C with 100 ml of the following coating antibodies
in PBS: 2 mg/ml anti–human IL-1b mAb or 5 mg/ml of anti–
human IL-1Ra mAb (both from R & D Systems, Inc.). After
washing in PBS/0.05% Tween 20 (33), the plates were blocked
for 1 h at room temperature (rt) using 300 ml 1% BSA/5% sucrose/
0.05% NaN3 in PBS. After three further washes, duplicate 100-ml
samples and dilutions of standard cytokines were then incubated
for 2 h at rt. After washing (34), 100 ml of the following biotiny-
lated detection antibodies were added in diluent (0.1% BSA,
0.05% Tween 20 in TBS, pH 7.3): 100 ng/ml anti–human IL-1b
antibody or 20 ng/ml anti–human IL-1Ra antibody (both from
R & D Systems, Inc.). After 2 h at rt, the plates were washed (35)
and 100 ml streptavidin horseradish peroxidase (Jackson Immu-
noresearch) at 1:5000 in diluent was added. After 20 min, six final
washes were followed by the addition of 100 ml of 3,39,5,59-tetra-
methylbenzidine hydrochloride solution in perborate (Sigma
Chemical Co.) to each well. The reaction was stopped by adding
50 ml/well 0.5 N H2SO4, and the plates were read at 450 nm in
an ELISA reader. The sensitivity of each cytokine ELISA was as
follows: IL-1b, ,1 pg/ml and IL-1Ra, 0.05 ng/ml.
Ribonuclease Protection Assay. 5 3 107 freshly isolated PBMCs
were used to obtain z5 3 106 adherent cells. This population of
cells is up to 90% monocytes by cytostaining and is 99% viable
(27). After resting overnight, the adherent cells were infected as
above with M. tuberculosis at 1:1. After 4 h, the cells were har-
vested, and total RNA was extracted using guanidinium isothio-
cyanate, CsCl2 density gradient centrifugation, and ethanol pre-
cipitation. 2 mg of the resultant RNA was hybridized overnight
according to the manufacturer’s instructions to a cocktail of
[32P]UTP (Du Pont)-labeled complimentary RNA probes (Phar-
Mingen) for IL-1a, IL-1b, IL-1Ra, IL-6, IL-10, IL-12 p40 and
p35, TNF-a and -b, TGF-b1–3, LT-b, and the housekeeping
genes L32 and GAPDH at 568C. Single-stranded RNA was di-
gested by incubation with RNase for 45 min at 378C and the
protected fragments reextracted by ethanol precipitation. The
products were electrophoresed on a 5% denaturing polyacryl-
amide gel; a negative control RNA and the unhybridized radio-
active probe were run in each experiment. The gel was exposed
overnight using a Biorad Geldoc 1000. The identity of the pro-
tected bands was confirmed by reference to the unhybridized
probes and quantitated by reference to bands for the housekeep-
ing genes L32 and GAPDH.
CFU Assay for the Intracellular Growth of M. tuberculosis. This
assay was performed as previously described with minor modifi-
cations (26). In brief, adherent cells were plated in triplicate wells
in 96-U microtiter plates (Corning Glass Works) and readhered
for 2 h. Cells were infected with M. tuberculosis H37Ra at 1:1, 10:1,
and 100:1 (bacillus/cell) in 30% autologous serum. After 2 h,
noningested bacteria were removed by washing gently (33) with
prewarmed RPMI 1640. Each well then received RPMI 1640
containing 2% autologous serum, and the plates were cultured in
a humidified incubator at 378C in the presence of 5% CO2 for as
little as 1 h (time 0 sample) up to 10 d. Duplicate wells contained
2 mg/ml of neutralizing anti–IL-1Ra (goat IgG; R & D Systems,
Inc.) or the same amount of isotype control antibody. At the end
of the culture period, supernates were aspirated, and the plates
containing the infected adherent cells were frozen at 2708C. To
determine the number of intracellular bacteria in the CFU assay,
the plates were thawed and cells lysed with 0.25% SDS in PBS
for 12 min and then neutralized using 20% BSA. The lysates were
then 10-fold serially diluted with 7H9 broth (Difco Labs., Inc.),
and three 10-ml aliquots of each dilution were plated on Middle-
brook 7H10 agar (Difco Labs., Inc.). The plates were then incu-
bated for 19 d at 378C in humidified air with 5% CO2. At the
end of this culture period, the number of CFUs in each of the
three replicate spots was enumerated for at least two consecutive
dilutions using a stereomicroscope and averaged. Using this tech-
nique, extracellular growth of mycobacteria as assessed by culture
of the supernates is consistently .1 log lower than intracellular
growth (26). The rate of intracellular growth expressed as dou-
bling time was determined by reference to the logarithmic
growth from the cultures.
Statistical Analysis. Values throughout are quoted or shown as
the mean 6 SE. Normally distributed variables were analyzed by
paired or unpaired t test. P values reflect two-tailed values of t.
Unpaired nonparametric variables were analyzed by the Mann-
Whitney U test. Contingency analysis was performed using Fisher’s
exact test of probability.
Results
Polymorphism in the IL-1Ra Gene Associates with the Stimu-
lated Production of IL-1Ra. First, we examined the M. tuber-
culosis–stimulated production of IL-1Ra by culture of 2.5 3
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106 PBMCs for 10 h. Culture supernates were assayed for
IL-1Ra content, and the results were normalized to the
number of monocytes in culture. The relationship between
polymorphism in IL-1RN in 17 donors homozygous for
the A1 allele (IL-1Ra A22) and 16 donors at least hetero-
zygous for A2 (3 A2/A2, 13 A1/A2; IL-1Ra A21) and the
M. tuberculosis–induced secretion of IL-1Ra was deter-
mined. The other alleles of IL-1RN were very rare and
therefore could not be assessed. The M. tuberculosis–stimu-
lated IL-1Ra response of A2/A2 homozygotes did not dif-
fer from A1/A2 (data not shown), confirming the previous
finding that IL-1Ra A2 is codominant (21). The unstimu-
lated production of IL-1Ra was slightly, but not signifi-
cantly, higher in the IL-1Ra A21 group (Fig. 1 A). Stimu-
lation by M. tuberculosis (0.1 and 1:1 bacillus/cell) caused a
dose-dependent increase in IL-1Ra secretion irrespective
of genotype. However, the median response of the IL-1Ra
A21 group was 1.9 times greater at both doses of M. tuber-
culosis tested (P 5 0.02 at 1:1). In a subset of 16 healthy
subjects, the dose response of IL-1Ra induction to PPD
was also determined (Fig. 1 B). Although IL-1Ra A22 in-
dividuals showed a dose-dependent increase in IL-1Ra se-
cretion, this did not become statistically significant until the
dose of PPD was 100 mg/ml. The response of IL-1Ra A21
individuals was 2.1–3.6 times higher, depending on the
dose. In contrast, induction of IL-1Ra in IL-1Ra A21 donors
was significant at 1 mg/ml. Thus, IL-1Ra A21 donors ap-
peared more sensitive to PPD stimulation. The median pro-
duction of IL-1Ra in response to LPS (10 mg/ml) was also
1.82 times greater in the IL-1Ra A21 donors (6.6 6 1.3 vs.
3.6 6 0.5 ng/ml/105 monocytes, P 5 0.012).
Relationship between Polymorphisms and the Production of
IL-1b. We next determined the level of IL-1b in the
same culture supernates used for the analysis of IL-1Ra. In
contrast to the IL-1Ra polymorphism, the two polymor-
phisms in the IL-1b gene did not correlate with the M. tuber-
culosis–stimulated production of IL-1b to the same extent.
The median M. tuberculosis (at 1:1)-stimulated production
of IL-1b in subjects positive for the 2511 A2 (n 5 20) was
635 6 119 pg/ml and 404 6 261 pg/ml in A1/A1 homo-
zygotes (n 5 8). The corresponding figures for the 13953
polymorphism were 404 6 84 pg/ml (A21, n 5 12) and
643 6 171 pg/ml (A1/A1 homozygotes, n 5 16). IL-1b
production did tend to be higher in IL-1Ra A22 subjects,
but only significantly so in response to M. tuberculosis at 0.1:1
(P 5 0.01) (data not shown).
As a pure antagonist of IL-1, IL-1Ra competes for occu-
pancy of IL-1RI, and it has been estimated that IL-1Ra needs
to be present in a large molar excess (25–503) to antagonize
IL-1b significantly (28). Therefore, the ratio of IL-1Ra/
IL-1b is likely to be more relevant to regulation of the in-
flammatory response than the absolute value of either cyto-
kine. The molar ratio of IL-1Ra/IL-1b was therefore calcu-
lated for each supernate and was significantly higher in IL-1Ra
A21 individuals (P # 0.05) in response to doses of both
M. tuberculosis and PPD at 1, 10, and 100 mg/ml (Fig. 2 B), in
some cases with only minor overlap between the groups. By
contrast, the response to LPS did not differ significantly be-
tween the groups. Fig. 2 B shows that the highest ratios likely
to result in antagonism of the IL-1b response to PPD and
M. tuberculosis stimulation (especially at lower doses likely to be
relevant to M. tuberculosis–infected foci) were observed in the
majority of IL-1Ra A21 individuals but only in a minority of
IL-1Ra A22 subjects. The bulk of the experiments were per-
formed using attenuated M. tuberculosis H37Ra. Therefore,
parallel determination of IL-1Ra and IL-1b secretion using
the same doses of M. tuberculosis H37Rv in three donors (one
A1/A1 and two A1/A2) was also performed. The level of
each cytokine was very similar, such that at an infection mul-
tiplicity of 1:1 the IL-1Ra/IL-1b ratio when stimulated by
H37Rv was 4.1, 16.8, and 12.6 for the three donors and 6.2,
17.3, and 8.0, respectively when stimulated by H37Ra. We
thus have no reason to suspect that the findings using M. tuber-
culosis H37Ra would not apply to virulent clinical isolates.
Figure 1. Association between IL-1Ra geno-
type and the monocyte production of IL-1Ra in
response to M. tuberculosis and PPD. The amount
of IL-1Ra produced by PBMCs from healthy,
PPD-nonreactive donors during a 10-h cocul-
ture with either M. tuberculosis (A) or PPD (B)
was determined by ELISA. Values were normal-
ized to the number of monocytes present in the
culture. The response of IL-1Ra A21 individuals
was higher at all doses of either stimuli.
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Cytokine Gene Expression by Ribonuclease Protection Assay.
We next sought to investigate association between the poly-
morphisms and the expression of mRNA. Ribonuclease
protection assay was performed on RNA from 13 donors,
all of different genotypes. The spontaneous expression of
IL-1Ra and IL-1b transcript was low. There was no con-
stitutive expression of any other monocyte cytokine, indi-
cating that this low expression was unlikely to have been
due to a nonspecific effect of cellular activation during iso-
lation. Within 1 h, M. tuberculosis induced IL-1Ra gene ex-
pression in all individuals, irrespective of genotype, together
with the mRNAs for IL-1b and TNF-a and followed
slightly later (2 h) by IL-1a and IL-6. At hour 4, there was
higher induction of IL-1Ra in the IL-1Ra A21 subjects
consistent with the protein data, although the difference
was not statistically significant (Table I). The IL-1b 13953
allele A2 was associated with significantly lower production
of IL-1b transcript (P 5 0.04). Taken together, we inter-
pret these observations to indicate that the alleles are associ-
ated with differences in transcription, but the dissociation
between induction and secretion, particularly in the case of
IL-1b, indicates that posttranscriptional mechanisms also
influence cytokine secretion.
Effect of Monocyte Cytokines on the Production of IL-1Ra in
Response to M. tuberculosis. The results so far showed that
in response to M. tuberculosis or its PPD, IL-1Ra gene ex-
pression is induced within 1 h, large quantities of protein
are secreted within 10 h, and differences between individu-
als could be related to their genotypes. However, an indi-
rect modulating influence of M. tuberculosis via increased
translation of preexisting IL-1Ra mRNA or an effect of
other cytokines (such as TGF-b, TNF-a, IL-1b, and IL-6)
produced by monocytes early in response to infection is
also possible. We investigated this possibility by assessing
the ability of antibodies known to neutralize the biological
effects of TGF-b, TNF-a, IL-1b, and IL-6 on M. tuberculo-
sis–stimulated production of IL-1Ra. Control wells re-
ceived isotype-matched antibodies. No consistent effect on
constitutive or stimulated IL-1Ra secretion was seen, irre-
spective of genotype, cytokine, or dose of antibody used
(up to 1,000-fold the ED50 concentrations). TGF-b modu-
lates the human response to tuberculosis (29, 30) and has
also been reported to increase IL-1Ra in some (31) but not
all studies (32). We therefore also evaluated the effect of
rTGF-b (0.1–10 ng/ml) on both M. tuberculosis–stimulated
and –unstimulated IL-1Ra production in 12 individuals
(6 IL-1Ra A22 and 6 IL-1Ra A21). No significant en-
hancement of the early secretion of IL-1Ra was seen (data
not shown). However, rIL-10 (0.1–10 ng/ml) caused a sig-
nificant dose-dependent increase in the M. tuberculosis–
stimulated IL-1Ra/IL-1b ratio in IL-1Ra A21 and IL-1Ra
A22 donors at all doses tested (P , 0.02), an effect largely
due to the suppression of IL-1b production (Fig. 3 A). The
addition of rhIL-6, however, caused no significant change
in the IL-1Ra/IL-1b ratio in either group.
Effect of T Cell Cytokines on the Production of IL-1Ra and
IL-1b in Response to M. tuberculosis. It has also been shown
that the lymphocyte production of IFN-g and IL-4 can dif-
ferentially modulate IL-1b and IL-1Ra production (33).
Our coculture system excluded the possibility of an obscur-
ing effect of T cell cytokines by the sole use of PBMCs
from PPD2 individuals and a short culture duration. In fact,
the production of IFN-g was negligible in the M. tuber-
culosis–stimulated cultures (20 pg/ml) from these subjects.
To investigate the possibility that T cell cytokines modu-
late M. tuberculosis–induced IL-1Ra and IL-1b secretion,
rhIFN-g or rhIL-4 were added (0.1–10 ng/ml) to cultures.
IL-4 caused a dose-dependent increase in both unstimu-
lated and M. tuberculosis–stimulated IL-1Ra production,
which was most significant in the M. tuberculosis–stimulated
Figure 2. Relationship be-
tween polymorphism in IL-1Ra
and the IL-1Ra/IL-1b ratio. The
IL-1b content of the supernates
shown in Fig. 1 was also assayed
by ELISA. The molar ratio of
IL-1Ra/IL-1b was calculated.
This ratio is selectively increased
in IL-1Ra A21 individuals in re-
sponse to PPD and M. tuberculosis,
accentuated by the finding that
IL-1Ra A21 subjects tended to
produce less IL-1b in response to
M. tuberculosis. By comparison, the
ratio in response to LPS was not
different between IL-1Ra A21
and A22 subjects. Response to
PPD is data from eight individuals.
Table I. Mean Fold Induction of the IL-1Ra and IL-1b Genes in 
Response to M. tuberculosis
Haplotype Number Fold induction* Range
IL-1Ra
A22 5 5.7 1.7–8.6
A21 8 10.0 2.6–29.5
IL-1b (2511)
A22 3 25.9 11.3–51.0
A21 10 46.5 23.7–84.7
IL-1b (13953)
A22 7 52.3 15.5–84.7
A21 6 29.3 11.3–47.5
Freshly isolated monocytes from 13 donors of differing genotypes were
rested overnight and then stimulated for 4 h with M. tuberculosis at 1:1.
Cytokine gene expression was quantitated by hybridization of 2 mg of
the resultant RNA to [32P]UTP-labeled complimentary RNA probes,
including L32 and GAPDH as constitutively expressed “housekeeping”
genes. The M. tuberculosis–induced fold increase in IL-1Ra or IL-1b
gene expression was calculated by dividing the band density in the pres-
ence of M. tuberculosis by the density in its absence.
*P values were 0.30 for IL-1Ra, 0.14 for IL-1b (2511), and 0.04 for
IL-1b (13953).
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IL-1Ra A21 group (P 5 0.002 at 10 ng/ml). Furthermore,
IL-4 also significantly decreased IL-1b production in M. tu-
berculosis–stimulated cells from both genotypes (P , 0.05 at
10 ng/ml). By comparison, IFN-g led to a dose-depen-
dent increase in M. tuberculosis–stimulated IL-1b produc-
tion that was most marked in the IL-1Ra A21 group (P 5
0.052 at 10 ng/ml). Thus, IFN-g tended to increase IL-1b
production in M. tuberculosis–stimulated cells without af-
fecting IL-1Ra production, whereas IL-4 increased IL-1Ra
production irrespective of genotype and also depressed
IL-1b secretion. This differential effect was reflected in the
mean M. tuberculosis–stimulated IL-1Ra/IL-1b ratio, which
increased in response to IL-4 even at the lowest dose of 0.1
ng/ml (P , 0.01, both groups combined). By comparison,
higher doses of IFN-g (1–10 ng/ml) were required to re-
duce the IL-1Ra/IL-1b ratio significantly (Fig. 3 B).
Relationship between Polymorphism in IL-1Ra and the Intra-
cellular Growth of M. tuberculosis. We next investigated the
effect of IL-1Ra polymorphism on the rate of intracellular
replication of M. tuberculosis. Monocytes from 22 donors
(12 IL-1Ra A22 and 10 IL-1Ra A21) were infected with
M. tuberculosis at various multiplicities (1:1, 10:1, and 100:1
bacillus/cell) and then cultured in vitro for up to 240 h.
Cell lysates were set up for M. tuberculosis CFU assay at 0,
24, 96, 168, and 240 h. Although there was interindividual
variation in the establishment of initial infection, there was
no significant difference between the IL-1Ra A22 and
IL-1Ra A21 groups. Logarithmic growth was established in
8 donors. The remainder showed either minimal or linear in-
tracellular growth of mycobacteria only, with no difference
between IL-1Ra A22 and IL-1Ra A21 donors. In those do-
nors in whom logarithmic growth did occur (5 IL-1Ra A22
and 3 IL-1Ra A21), the doubling time of M. tuberculosis was
estimated from the growth curve. Data from these individ-
uals is shown in Table II. Intra- and interindividual differ-
ences did not appear to be related to the presence or ab-
Figure 3. (A) Effect of IL-6 and IL-10
on the IL-1Ra/IL-1b ratio. PBMCs were
cultured with M. tuberculosis in the presence
or absence of rhIL-6 or rhIL-10 over a
dose range of 0.1–10 ng/ml. Culture su-
pernates were assayed for IL-1Ra and
IL-1b and the molar ratio calculated. IL-10
increased the ratio significantly even at the
lowest dose (P , 0.02), whereas rhIL-6
had no significant effect. (B) Effect of
IFN-g and IL-4 on the IL-1Ra/IL-1b ra-
tio. PBMCs were cultured with M. tubercu-
losis in the presence or absence of rhIFN-g
or rhIL-4 over a dose range of 0.1–10
ng/ml. Culture supernates were assayed for
IL-1Ra and IL-1b and the molar ratio cal-
culated. IL-4 increased the ratio markedly
even at the lowest dose (P , 0.01),
whereas higher doses of IFN-g were re-
quired to cause a significant reduction.
Table II. Lack of Relationship between IL-1Ra Polymorphism and 
the Intracellular Growth of M. tuberculosis In Vitro
Donor Genotype
Culture
duration
Doubling times at various
multiplicities of infection
by M. tuberculosis (h)
1 10 100
h
1 A1/A1 96 24 (2.47) 22 14
2 A1/A1 168 2 2 22
3 A1/A1 240 39 (2.56) 32 2
4 A1/A1 240 38 (1.45) 2 2
5 A1/A1 240 42 28
6 A1/A2 96 27 (10.65) 15 13
7 A1/A2 168 38 25 27
8 A1/A2 240 53 (10.67) 29 2
Doubling times were estimated from the logarithmic growth curve in
each case. The numbers in parentheses show the IL-1Ra level in ng/
ml/100,000 monocytes for the same individual at the corresponding
multiplicity of infection.
2, Not tested.
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sence of the IL-1Ra A2 allele. These data therefore contrast
with the readily demonstrable increase in IL-1Ra secretion
conferred by the A2 allele in the same donors (shown in
parentheses in Table II). In each experiment, triplicate
wells were also included to assess the effect of 2 mg/ml
neutralizing antibody to IL-1Ra (and goat IgG isotype
control). No consistent effect of these antibodies on intra-
cellular growth was seen (data not shown).
IL-1b and IL-1Ra Genotype and Allele Frequency in Tubercu-
losis Patients and Control Subjects. We next sought in vivo
correlates by determination of the frequency of the IL-1b
and IL-1Ra polymorphisms in patients with tuberculosis and
healthy PPD-reactive control subjects in a pilot case-control
analysis of Gujarati asians in west London. This population is
distinct and has a high incidence of tuberculosis with an ex-
cess of extrapulmonary forms. Individual alleles at each locus
were in Hardy-Weinberg equilibrium. The IL-1b (2511)
allele 1 was in linkage disequilibrium with IL-1b (13953)
allele 2 and vice-versa (P , 0.03). In addition, there was
weaker linkage between IL-1Ra A2 and IL-1b (13953) A2.
No allele or genotype, singly or in combination, was associ-
ated with an increased risk of tuberculosis (Table III). We
concluded that, in this population, these polymorphisms
have little effect on susceptibility to tuberculosis per se.
The in vitro data indicated that the IL-1Ra A22/IL-1b
(13953) A11 haplotype was associated with low IL-1Ra
protein and gene expression and higher corresponding IL-1b
values, implying a proinflammatory phenotype. We there-
fore examined association between the gene polymorphisms
and the presenting form of post-primary tuberculosis (Table
IV). This proinflammatory haplotype was more common in
patients with pleural disease (P 5 0.028 by comparison with
control subjects). Pleural tuberculosis represents a contained
disease phenotype associated with a high DTH response and
marked proinflammatory cytokine responses at the site of
disease (34, 35). By comparison, the IL-1Ra A2 was more
common in patients with extrapulmonary disease (P 5
0.009, by comparison with pleural disease). A similar reduc-
tion in DTH as manifested by cutaneous reactivity to PPD
was also associated with the presence of the IL-1Ra A2 al-
lele: the proportion of IL-1Ra A21 individuals progressively
decreased at higher grades of Mantoux (Table IV, Fig. 4).
Discussion
We have investigated the effect of polymorphisms in the
IL-1b and IL-1Ra genes on M. tuberculosis–stimulated cyto-
Table III. IL-1Ra and IL-1b Allele and Genotype Frequencies in 
Tuberculosis Patients and Tuberculin-reactive Healthy Control Subjects
Gene Position
Genotype or allele
frequency Patients Controls
IL-1Ra N/A A1 0.713 0.719
A2 0.236 0.241
A3 0.045 0.039
A4 0.006 0
A1/A1 51 (57%) 65 (57%)
A1/A2 21 (24%) 30 (26%)
A2/A2 9 (10%) 10 (9%)
Others* 8 (9%) 9 (8%)
IL-1b 2511 A1 0.438 0.404
A2 0.562 0.596
A1/A1 20 (22%) 18 (16%)
A1/A2 38 (43%) 56 (49%)
A2/A2 31 (35%) 40 (35%)
IL-1b 13953 A1 0.837 0.794
A2 0.163 0.206
A1/A1 64 (72%) 76 (67%)
A1/A2 21 (24%) 29 (25%)
A2/A2 4 (4%) 9 (8%)
Numbers in italics represent allele frequencies in each group for each lo-
cus. The numbers in plain text represent the number (accompanied by
the percentage) of individuals with a given genotype. There are no sig-
nificant differences in allele or genotype frequencies between patients
(n 5 89) and healthy control subjects (n 5 114) at any of the three loci.
*Patients: three A1/A3, one A3/A3, one A1/A4, and three A2/A3;
controls: four A1/A3 and five A2/A3.
Table IV. Relationship between IL-1Ra/IL-1b Haplotype and 
Disease Phenotype
Groups
IL-1Ra A22/IL-1b
(13953) A11
Other
haplotypes* P
Total controls 65 (57%) 49 (43%)
Total patients 54 (61%) 35 (39%) 0.67
Pleural 11 (92%) 1 (8%) 0.028
Pulmonary 16 (62%) 10 (38%) 0.83
Miliary 6 (60%) 4 (40%) 1
Lymphadenopathic 12 (60%) 8 (40%) 1
Extrapulmonary‡ 9 (43%) 12 (57%) 0.24
Median Mantoux/mm 15.5 6 1.4 11.5 6 1.8 0.068
The number of patients with varying disease forms bearing the IL-1Ra
A22/IL-1b (13953) A11 haplotype is compared to the number bear-
ing other combinations. This haplotype was associated with low IL-
1Ra protein and gene expression and higher corresponding IL-1b val-
ues in vitro, implying a proinflammatory phenotype. The haplotype was
more common in pleural disease, a form in which DTH is thought to
be high, and was also associated with a moderately greater reaction to
PPD in vivo. P values were calculated relative to the control group by
Fisher’s exact test of probability, except for the comparison of median
Mantoux diameter within the patient group, which was performed by
the Mann-Whitney U test.
*Controls: 40 IL-1Ra A21/IL-1b (13953) A11, 5 IL-1Ra A21/IL-1b
(13953) A12, and 4 IL-1Ra A22/IL-1b (13953) A12; patients: 31
IL-1Ra A21/IL-1b (13953) A11, 2 IL-1Ra A21/IL-1b (13953)
A12, and 2 IL-1Ra A22/IL-1b (13953) A12.
‡10 osteomyelitis, 2 adrenal, 2 ileocaecal, 2 psoas, 2 synovial, 1 thigh
abscess, 1 pericardial, and 1 peritoneal.
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kine production in vitro and their relevance in patients with
tuberculosis. When compared with healthy IL-1Ra A22
subjects, A21 subjects as a group secreted nearly twice as
much IL-1Ra in response to both laboratory-adapted and
virulent M. tuberculosis, PPD, or LPS. The mean fold
induction of IL-1Ra mRNA was also nearly twice that of
IL-1Ra A22 subjects. The two polymorphisms in the IL-1b
gene were not clearly associated with the level of M. tuber-
culosis–stimulated IL-1b production in vitro, although the
IL-1b (13953) A11 haplotype was associated with signifi-
cantly increased M. tuberculosis–induced expression of the
IL-1b gene. The individual molar ratios of IL-1Ra/IL-1b,
which determine the net effect of these cytokines in re-
sponse to PPD and M. tuberculosis, were clearly higher in
IL-1Ra A21 subjects. Furthermore, the IL-1Ra/IL-1b ra-
tios were affected by cytokines, as IL-4 upregulated IL-1Ra
production and downregulated IL-1b production. IL-10
greatly suppressed and IFN-g moderately enhanced the
production of IL-1b. In patients with tuberculosis, the
proinflammatory IL-1Ra A22/IL-1b (13953) A11 haplo-
type was unevenly distributed, being more common in pa-
tients with pleural disease and less common in those with
extrapulmonary disease. A further finding, consistent with
the in vitro observations, was that the IL-1Ra A21 haplo-
type was associated with a reduced Mantoux response to
PPD of M. tuberculosis: 60% of tuberculin-nonreactive pa-
tients were of this type.
Our study of IL-1RN gene expression indicates the early
induction by M. tuberculosis of its mRNA together with IL-1b,
IL-1a, TNF-a, and IL-6. Although IL-1Ra A2 was associ-
ated with an increased induction of the IL-1RN gene, the
exact mechanism of increased IL-1Ra production requires
further elucidation. Whereas the fold induction of IL-1b
mRNA was higher than that of IL-1Ra and could also be
related to both IL-1b polymorphisms, the amount of se-
creted IL-1b protein was much less. In addition, the IL-1b
polymorphisms could not so readily be related to protein
secretion. This observation is consistent with other data
(36) and indicates a dominant influence of both posttran-
scriptional and posttranslational events on the secretion of
IL-1b. Many cytokines can upregulate IL-1Ra expression
in vitro (17). The production of IL-1Ra, however, was un-
affected by antibody neutralization of IL-1b, IL-6, TGF-b,
and TNF-a, suggesting that M. tuberculosis or its products
induce the early production of large quantities of IL-1Ra
by a direct mechanism.
IL-1b is involved in the early recruitment of inflamma-
tory cells to M. tuberculosis– or PPD-induced granulomas
(37–41). Submaximal occupancy of IL-1RIs can mediate
the full biological effects of IL-1b, and as a consequence, it
has been postulated that IL-1Ra needs to be present in a
large molar excess in order to exert its antagonism (28). In
tuberculosis, this condition would be best fulfilled in IL-1Ra
A21 subjects (Fig. 2); the IL-1Ra A2 allele was associated
with reduced DTH (Fig. 4) and was lower in frequency in
patients with pleural tuberculosis, consistent with the in
vitro data and suggestive of biological significance. Anti-
gen-specific lymphocytes are also necessary for the DTH
reaction to proceed. In our experiments, IL-4 increased
IL-1Ra secretion, particularly in stimulated cultures from
IL-1Ra A21 subjects (Fig. 3 B). The production of IL-4 in
tuberculosis has been best demonstrated in T cell clones
(42), but one study has also documented small amounts of
antigen-specific secretion of IL-4 by PBMCs (43). As cell-
associated IL-4 is a stimulus for IL-1Ra, there is the possi-
bility that relatively small amounts of IL-4 may greatly af-
fect the IL-1Ra response (33). IFN-g decreased and IL-10
increased the IL-1Ra/IL-1b ratio mainly through an effect
on IL-1b secretion. Both IFN-g and IL-10 are produced
by PBMCs and at disease sites in patients with tuberculosis
(29, 44, 45). Our data therefore suggests that the polymor-
phism in the IL-1Ra gene may exert regulatory influence
on cytokine circuits beyond its direct effect on IL-1Ra
production.
There is both epidemiological and experimental evi-
dence of a dissociation between DTH and protection from
tuberculosis (46, 47). Our finding that IL-1Ra appears to
influence DTH with minimal effect on either the intracel-
lular growth of M. tuberculosis in vitro or disease susceptibil-
ity in the case-control study further suggests a basis for the
dissociation between DTH and susceptibility. In addition
to disease susceptibility, the degree of cutaneous reactivity to
PPD after bacille Calmette-Guérin vaccination in both mono-
and dizygotic twins and in siblings is also heritable (48, 49).
Our in vitro data (Figs. 1 and 2) clearly suggest a functional
basis for the observed association between reduced DTH
and A2 of the IL-1RN gene. Although our case-control
analysis was modest in size, there was a distinct difference in
IL-1Ra A21 frequency between patients with pleural and
extrapulmonary tuberculosis, and this preliminary data en-
courages us to determine in larger studies whether this as-
sociation is generalizable to other populations. As our data
also support a heritable component in the quantitative skin
response to PPD, another appropriate strategy would be to
perform a genome-wide search, which may not only con-
firm the involvement of the IL-1 locus but also potentially
identify loci of relevance to other infectious processes as
well (50). As the frequency of the IL-1Ra A2 allele is ap-
proximately six times lower in Gambia (51) and also in
Kenya (Wilkinson, R.J., and P.A. Zimmerman, unpublished
Figure 4. Association between
IL-1Ra haplotype and the cuta-
neous response to PPD of M. tu-
berculosis. The mean diameter of
induration in response to one tu-
berculin unit of PPD in tubercu-
losis patients of various genotypes
is shown. The proportion of
IL-1Ra A21 was highest (60%) in
patients with an absent response
and lowest in the category 21–30
mm (25%), falling gradually to its
overall frequency (41%) as succes-
sively higher grades of Mantoux
were considered.
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observations), perhaps this gene has been subject to natural
selection by different major infectious diseases in India or
Africa. It would also be interesting to determine whether a
high IL-1Ra allele A2 frequency is present in populations
with a high degree of PPD “anergy” (3).
The association between the IL-1Ra genotype and disease
expression supports the hitherto unproven concept that host
genes can influence disease phenotype in tuberculosis (52).
We propose that the early recruitment and activation of in-
flammatory cells by IL-1b to foci of tuberculous infection
is in turn downregulated by IL-1Ra that, under polymor-
phic host control, acts to limit the resultant DTH. This hy-
pothesis could be readily tested in IL-1 and IL-1Ra gene
knockout mice (53, 54). Reduction of DTH by targeted
immunotherapy with either IL-1Ra or other engineered
antagonists of IL-1RI (55) may also be a possible approach
to modulation of immunopathologic cytokine circuits in
tuberculosis.
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